News Article | May 11, 2017
PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it has received the approval from the US regulatory authorities for the recruitment of sarcopenia patients in the observational study SARA-OBS on Sarconeos. It has therefore been able to open the two clinical centers and start the recruitment of sarcopenia patients in the United States. These patients, if they give their consent, could participate in the clinical trial of phase 2b SARA-INT, on Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are delighted to announce the recruitment of the first patient in the SARA-OBS clinical study in the United States. The US clinical centers of Boston and Gainesville are now open and recruiting patients. These centers are specialized in sarcopenia patients care, led by internationally renowned clinicians, and ideally complete our European clinical network. It marks an important step of our development strategy in the US, our primary market, which was announced one year ago. We are now focusing on the preparation of the interventional phase, SARA-INT, which will follow on this observational study.” BIOPHYTIS has obtained the authorization of the regulatory authorities to start the SARA-OBS clinical study in sarcopenia. The first two clinical centers have therefore been opened, in Boston at the Jean Mayer Human Nutrition Research Center on Aging, Tufts University with head investigator Professor Roger Fielding, and in Gainesville at the Institute of Aging, University of Florida, with investigator Professor Marco Pahor. The recruitment of the 300 patients in the 8 clinical centers opened in Europe (France, Belgium and Italy) and the United States has now begun. Sarcopenia patients will be monitored for 6 months before being possibly included in the interventional phase 2b SARA-INT study, after obtaining their consent. The opening of centers in the United States is a critical marker of the development strategy initiated a year ago. It consists in a doubling of the size of the clinical study by recruiting patients in the US (the most important market for BIOPHYTIS in terms of number of patients), opening of a subsidiary in Boston, recruitment of reputable clinicians, in particular Roger A Fielding who joined BIOPHYTIS’ Scientific Advisory Board, and is the head researcher of the SARA-OBS/SARA-INT study. To know more about the SARA clinical program and Sarcopenia, you may also watch the introductory video by following this link: http://www.biophytis.com/en/actualites/SARA-ICFSR-2017/ About SARA-OBS: SARA-OBS is a 6-months clinical observational study, conducted in over 300 sarcopenia patients recruited in 8 clinical centers in Europe and the United States. Patients’ mobility and muscular quality will be assessed, based on the following criteria: 6-minute walk test, mobility (SPPB test), muscle strength (grip test), body composition and plasmatic parameters. Data from SARA-OBS will provide a better characterization of the target population for the Sarconeos treatment. Patients in the SARA-OBS study will be included in the phase 2b study of SARA-INT at the end of 6 months, once consent is given. ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people. This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). BIOPHYTIS is eligible for the SMEs scheme Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.
News Article | May 25, 2017
The emerging discipline of space meteorology aims to reliably predict solar flares so that we may better guard against their effects. Using 3D numerical models , an international team headed by Etienne Pariat, a researcher at LESIA (Observatoire de Paris / CNRS / Université Paris Diderot / UPMC), has discovered a proxy that could be used to forecast an eruptive event. The proxy is associated with magnetic helicity, which reflects the extent of twist and entanglement of the magnetic field. The study is published in the journal Astronomy and Astrophysics dated 17 May 2017. Solar flares or eruptions are one of the most violent phenomena in the Solar System. They coincide with a sudden, violent reconfiguration of the magnetic field, releasing huge amounts of energy that can eject billions of tons of solar material into space at speeds of over a thousand kilometers per second. Although numerous parameters have been studied, the probability of forecasting a major flare one day in advance is currently no greater than 40%. And yet the most powerful flares can lead to major disruptions on Earth, causing interference with telecommunications or knocking out electrical power grids across entire regions of the world. Our technologies, which are increasingly dependent on electrical components and on satellites (GPS, telephony, etc), are thus ever more sensitive to solar activity, while such flares can even put astronauts' lives in danger. One of the aims of space meteorology is to forecast solar flares, in the same way as meteorological services forecast storms on Earth. Looking for a predictive parameter, the astrophysicists based their work on 3D numerical simulations, which use computers to reproduce the behavior of the magnetic field in the Sun's atmosphere as well as the formation of sunspots, where eruptions take place. The researchers tested various parametric simulations and analyzed changes in magnetic energy and magnetic helicity, a quantity that measures the extent of entanglement and twist of the magnetic field. For their study, the researchers carried out computer simulations of two scenarios, one with an eruption and the other without. Their initial calculations confirmed that neither magnetic energies nor the total helicity of the magnetic field fulfilled the criteria for a predictive factor. Using a complex mathematical approach based on the separation of the magnetic field into several components, the researchers successfully obtained a proxy capable of predicting eruptions. The proxy (which compares two helicities in the potentially eruptive region) remains low in non-eruptive scenarios; whereas in every other case it increases significantly before the eruption. The study, carried out as part of the HéliSol program, thus opens the way to more effective forecasting of solar flares. The theoretical findings now need to be confirmed by analyzing observations of active solar regions. This is currently being done as part of the European Flarecast project, which aims to set up an automatic system for forecasting flares.
News Article | May 23, 2017
Soliant Health, a leading specialty healthcare staffing provider and part of Adecco Group, is now accepting votes for its ninth annual Most Beautiful Hospitals in the U.S. contest. Between May 22 and June 23, Soliant is accepting votes for its 2017 Most Beautiful Hospitals in the U.S. contest on mostbeautifulhospitals.com. Voters are encouraged to vote as many times as they can over this 4-week voting period. There is no limit on how many votes an individual can cast per day up until the voting period closes on June 23. Winners will be announced on June 26. “Doctor’s Memorial Hospital, our 2016 winner, showed us that smaller critical access hospitals can make a big impact on several accounts,” said David Alexander, president of Soliant Health. “An impact not only on the lives they serve, but also on the innovation of hospital design and efficiency of care – two integral commitments they have sustained for more than five decades.” Doctors Memorial Hospital in Bonifay, Fla. earned Soliant’s Most Beautiful Hospital in the U.S. distinction in 2016 with almost 40,000 votes. Located at the heart of Florida’s Panhandle, this critical-access hospital has served the Bonifay population for more than 50 years. It was rebuilt from the ground up in 2008, doubling its size and splitting its floor plan into two distinct components, one for business and the other for medical services, which maintains patient privacy away from public business operations. Doctor’s Memorial Hospital has appeared on Soliant’s Top 10 rankings three times in past years. This year's nominations include facilities from all across the United States: Baylor Scott & White All Saints Medical Center's Andrews Women's Hospital — Fort Worth, TX Broughton Hospital — Morganton, NC Children's Hospital at Sacred Heart — Pensacola, FL Children's Hospital of Pittsburgh of UPMC — Pittsburgh, PA Christus Highland Medical Center — Shreveport, LA Cobb Hospital — Austell, GA Dell Children's Medical Center — Austin, TX Doctors Memorial Hospital — Bonifay, FL Dr. Phillips Hospital — Orlando, FL Elmhurst Memorial Hospital — Elmhurst, IL Eskenazi Hospital — Indianapolis, IN FirstHealth Moore Regional Hospital — Pinehurst, NC Flagler Hospital — St. Augustine, FL Greenville Memorial Hospital — Greenville, SC Henry Ford Hospital West Bloomfield — West Bloomfield Township, MI Intermountain Medical Center — Murray, UT JFK Medical Center — Edison, NJ Kettering Medical Center — Kettering, OH La Rabida Children's Hospital — Chicago, IL Marianjoy Rehabilitation Hospital — Wheaton, IL McKay-Dee Hospital — Ogden, UT Memorial Healthcare System - Miramar — Hollywood, FL Mercy Hospital — Folsom, CA Methodist Hospital — Philadelphia, PA Mosaic Life Care — St. Joseph, MO Norton Sound Regional Hospital — Nome, AK Oaklawn Hospital — Marshall, MI Orange Regional Medical Center — Middletown, NY PinnacleHealth West Shore Hospital — Mechanicsburg, PA Poway Healthcare Center — Poway, CA Primary Children's Hospital — Salt Lake City, UT Riverview Medical Center — Red Bank, NJ Sanford Health — Bismarck, ND Sioux Center Health — Sioux Center, IA St. Francis Hospital — Flower Hill, NY St. Jude Children's Research Hospital — New York, NY Summit Pacific Medical Center — Elma, WA WellStar Kennestone Regional Medical Center — Marietta, GA Winnie Palmer Hospital — Orlando, FL To cast your vote and to learn more about last year’s winners, visit mostbeautifulhospitals.com. For more information about Soliant Health, visit soliant.com. About Soliant Health Soliant Health, an Adecco Group company, is one of the largest healthcare staffing companies in the country. Soliant Health connects hospitals and healthcare providers with highly qualified, full- or part-time healthcare professionals in a variety of specialized disciplines. Soliant's teams of professionals are qualified to fill physician, nursing, therapy, pharmacy, and other healthcare positions. For further information, please contact: Tera Tuten Vice President of Operations Soliant Health 904-527-5826 tera.tuten(at)soliant(dot)com
News Article | June 23, 2017
PITTSBURGH, June 23, 2017 - Researchers at the University of Pittsburgh School of Medicine and the University of Toronto have uncovered the first molecular steps that lead to immune system activation and eventual rejection of a transplanted organ. The findings, published today in Science Immunology, may be used someday to create better donor-recipient matches and develop new ways to prevent rejection of transplanted tissues. Approximately 50 percent of all transplanted organs are rejected within 10 to 12 years, so there is a great need for better ways to reduce or eliminate organ rejection, explained the study's co-senior author Fadi Lakkis, M.D., Frank & Athena Sarris Chair in Transplantation Biology and scientific director of Pitt's Thomas E. Starzl Transplantation Institute (STI). "For the first time, we have an insight into the earliest steps that start the rejection response," Lakkis said. "Interrupting this first recognition of foreign tissues by the innate immune system would disrupt the rejection process at its earliest inception stage and could prevent the transplant from failing." UPMC has been a worldwide leader in organ transplantation for more than 35 years. Throughout its history, the University of Pittsburgh Transplantation Institute, renamed the STI in 1996 in honor of liver transplant pioneer Dr. Thomas E. Starzl, has been creating innovative transplantation strategies. "This study is the latest example of the STI's commitment to improving the lives of patients with organ failure," Lakkis said. The immune system is composed of innate and adaptive branches. The innate immune system is the first to detect foreign cells in the body and is required to activate the adaptive, or acquired, immune system. The mechanisms underlying this second phase of immune activation following organ transplantation are well studied, but the details of how innate immunity contributes to rejection have, until now, remained unknown. In the new study, researchers used a classical genetic mapping approach to show that in mice a molecule called SIRP-alpha leads to innate immune system activation and differs between unrelated individuals. When the transplanted tissue SIRP-alpha is different from the host tissue SIRP-alpha, the transplant SIRP-alpha binds to a receptor called CD47 that is located on the recipient's monocytes, a class of innate immune cells. This binding kicks off a series of cellular events that activate the innate and then eventually the adaptive immune system. Like mice, humans also express SIRP-alpha, so sequencing the gene to identify donors and recipients with matched forms of the molecule hopefully will lead to lower organ rejection rates in the future, Lakkis said. Blocking the interaction between SIRP-alpha and CD47 in mice prevented the monocyte activation, suggesting that disruption of this coupling could prevent recipient immune system activation. Future studies to examine how the interaction between SIRP-alpha and CD47 leads to monocyte activation could lead to new ways to prevent organ rejection. Additional authors on the study were co-senior author Jayne Danska, Ph.D., of the Hospital for Sick Children and University of Toronto; Hehua Dai, M.D., Andrew Friday, Ph.D., Khodor Abou-Daya, M.D., Amanda Williams, M.S., Matthew Nicotra, Ph.D., David Rothstein, M.D., Warren Shlomchik, M.D., Jeffrey Isenberg, Ph.D., and Martin Oberbarnscheidt, M.D., Ph.D., all of Pitt; Steven Mortin-Toth of the Hospital for Sick Children; and Takashi Matozaki, M.D., Ph.D., of Kobe University. Funding was provided by National Institutes of Health grants AI099465 and AI049466, and the American Heart Association. The University of Pittsburgh Schools of the Health Sciences include the schools of Medicine, Nursing, Dental Medicine, Pharmacy, Health and Rehabilitation Sciences and the Graduate School of Public Health. The schools serve as the academic partner to the UPMC (University of Pittsburgh Medical Center). Together, their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease and participate in the delivery of outstanding patient care. Since 1998, Pitt and its affiliated university faculty have ranked among the top 10 educational institutions in grant support from the National Institutes of Health. For additional information about the Schools of the Health Sciences, please visit http://www. .
News Article | June 15, 2017
PITTSBURGH, June 15, 2017 - Researchers at University of Pittsburgh School of Medicine and UPMC have discovered a clue that could unlock the potential of immunotherapy drugs to successfully treat more cancers. The findings, published in Cell, were made in mice and showed that targeting a sub-population of immune cells called regulatory T cells could be an effective approach to treating cancers. The findings also point to what could be an important mechanism by which current immunotherapy drugs work, providing clues to making them more effective. Immunotherapy drugs that push the immune system to detect and kill cancer cells have been successful against several cancers, yet they are still only effective in approximately 10 to 30 percent of patients with certain tumor types. Exactly why these drugs don't work in more patients has remained a mystery. The discovery points to what could be an important mechanism by which current immunotherapy drugs work, providing clues to making them more effective. Regulatory T cells (Tregs; pronounced "tee-regs") help maintain a delicate balance in our immune system. "They act like a dimmer switch, keeping the lights bright enough to detect and eliminate threats, but not so bright that our own cells are hurt," said Dario Vignali, Ph.D., who holds the Frank Dixon Chair in Cancer Immunology, and is professor and vice chair of immunology at Pitt's School of Medicine. "In cancer, Tregs can be detrimental because by turning down the lights, they prevent the immune system from detecting and killing cancer cells. While creating drugs to eliminate Tregs may seem like a logical approach to treatment, they could lead to life-threatening autoimmune complications, making them unusable in cancer patients. Thus, we need to identify approaches that selectively target Tregs in tumors, sparing those outside the tumor," said Vignali, who also is co-director of the Cancer Immunology Program at the UPMC Hillman Cancer Center. A few years ago, Vignali and his colleagues discovered that a surface protein called neuropilin-1 (Nrp1), which is expressed on almost all Tregs that infiltrated mouse tumors, was required to maintain the function, integrity and survival of Tregs within the harsh tumor microenvironment. Thus, Nrp1 on Tregs helps suppress the body's natural anti-tumor immune response thereby helping the tumor survive. Importantly, blocking or deleting Nrp1 in Tregs in mice only impacted their function in tumors and not in the rest of the body, resulting in tumor eradication without inducing autoimmune or inflammatory disease. "What we've shown in the current study is that in mice, Nrp1 expression by Tregs is required to maintain their ability to prevent the immune system from clearing the tumor. Interestingly, when Tregs lose Nrp1, they not only fail to suppress, they also become active participants in the anti-tumor immune response," said Vignali. "Intriguingly, we also found that in cancer patients who had a poor prognosis, the Nrp1-expressing Treg subset was much higher, suggesting that the findings could apply to humans as well." To arrive at their findings, the research team created a genetically modified mouse model in which the Nrp1 gene was deleted in only half the Treg cell population, but not the other half. Tumor growth in this model, they found, was dramatically reduced when compared to a normal mouse in which Nrp1 was present in all Tregs. "Not only did Tregs without Nrp1 have a reduced ability to turn down the lights, they also prevented the normal Treg population from performing their own immunosuppressive functions. This allowed the immune system to see and attack the tumor," said Abigail E. Overacre-Delgoffe, a graduate student in Vignali's lab and the first author of the Cell study. Genomic and cellular analyses revealed that a secreted immune molecule called interferon-gamma (IFNγ) prevented the dimmer switch function of Tregs in the mice, particularly and selectively in the tumor microenvironment. Using another genetically modified mouse model, they found that the role of IFNγ in diminishing Treg function was crucial to the success of immunotherapies targeting the PD1 protein that have been proven to be very effective in patients. "While we thought that IFNγ might impact the function of Tregs and thus influence immunotherapy outcome, the magnitude of the effect really took us by surprise. When we deleted the receptor for IFNγ in Tregs so they were no longer sensitive to the impact of IFNγ, the immunotherapy drug had absolutely no effect," said Vignali. "In essence, IFNγ seems to make Tregs fragile so that they lose their suppressive function, but only in the tumor. Thus, maybe making Tregs fragile is a critical requirement for effective immunotherapy." Overall, the authors note that their findings are significant because they show that if we can get a portion of the tumor-associated Tregs to lose their immunosuppressive functions--possibly by using IFNγ--it may be enough to set off a chain reaction where these cells can influence other tumor-associated Tregs, consequently promoting anti-tumor immunity without the adverse autoimmune side effects. Additionally, in the near-term, tracking Treg functional fragility may prove to be an effective approach to monitor whether immunotherapy treatments are effective in patients. Additional authors on the study are Maria Chikina, Ph.D., Rebekah E. Dadey, Hiroshi Yano, Ph.D., Erin A. Brunazzi, Gulidanna Shayan, William Horne, Ph.D., Jessica M. Moskovitz, Jay K. Kolls, M.D., Cindy Sander, Yongli Shuai, Daniel P. Normolle, Ph.D., John M. Kirkwood, M.D., Robert L. Ferris, M.D., Ph.D., Greg M. Delgoffe, Ph.D., Tullia C. Bruno, Ph.D., and Creg J. Workman, Ph.D., all of Pitt. The study was supported by National Institutes of Health grants R01 CA203689, F31 CA189441, CA047904, CA21765, CA097190, CA121973, P30 CA047904, S10 OD011925, S10 OD019942, and the American Lebanese Syrian Associated Charities. Vignali and Delgoffe have disclosed competing financial interests and have submitted patents regarding Nrp1 that are pending or granted. As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support. Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see http://www. . A $14 billion world-renowned health care provider and insurer, Pittsburgh-based UPMC is inventing new models of patient-centered, cost-effective, accountable care. UPMC provides nearly $900 million a year in benefits to its communities, including more care to the region's most vulnerable citizens than any other health care institution. The largest nongovernmental employer in Pennsylvania, UPMC integrates 65,000 employees, more than 25 hospitals, 600 doctors' offices and outpatient sites, and a more than 3.2 million-member Insurance Services Division, the largest medical and behavioral health services insurer in western Pennsylvania. Affiliated with the University of Pittsburgh Schools of the Health Sciences, UPMC ranks No. 12 in the prestigious U.S. News & World Report annual Honor Roll of America's Best Hospitals. UPMC Enterprises functions as the innovation and commercialization arm of UPMC while UPMC International provides hands-on health care and management services with partners in 12 countries on four continents. For more information, go to UPMC.com.
Upmc | Date: 2011-02-07
An apparatus includes a container and a content identification device providing an audible identification of the contents of the container. The container can be included in an automatic dispensing system. A method is also provided. The method includes providing a container, and producing an audible identification of contents of the container in response to one of: opening the container, a request to access the contents of the container, or actual access of the contents of the container by a user.
Upmc | Date: 2012-07-06
A system and method for improved viewing and navigation of large digital images, such as whole slide images used in microscopy. The system and method displays the digital image along with movable navigation and field of view boxes that enable a viewer to pan the digital image in an accurate manner, and also performs automatic absolute reorientation of the digital image and automatic relative reorientation of subsequent digital images in relation to the first digital image.
Upmc | Date: 2015-02-19
A system for processing healthcare information includes: a patient clinical context module including a patient-user relationship model, a medical knowledge database, and an applied workflow execution model; the patient clinical context module being configured to retrieve information from a plurality of data sources and to use the patient-user relationship model, the medical knowledge database, and the applied workflow execution model to produce output information relevant to a patient; and a user display configured to display the output information in a longitudinal view of health data for the patient aggregated from the plurality of data sources. A method for processing healthcare information that can be implemented by the system is also disclosed.
Upmc | Date: 2013-01-03
An apparatus includes a computer system programmed to retrieve information from a plurality of data sources; the computer system including a plurality of vault query services; an adapter for each of the data sources, each adapter translating an interface for one of the data sources to a vault query service interface; and a cross-vault query service providing an interface for data communication between an application program and the plurality of vault query services; and a user display for displaying the information retrieved from the data sources in response to a query from the application program.
Upmc | Date: 2014-06-09
A method for processing healthcare information includes: receiving information related to a patient and a plurality of providers involved with caring for the patient; using the information to generate patient centered provider graphs that describe relationships among the patient and the plurality of providers and include an indication of provider availability within a clinical situation; and presenting the graphs to a plurality of uses. An apparatus that is used to practice the method is also provided.